Click here for the CME evaluation / post-test

Activity Index
Click on the titles below to view the presentations.

Thursday, October 19, 2007 – General Session

Myeloma Section

Session I: Cell cycle in myeloma
Chair: Scott Ely, MD

Plasma cell proliferation, cell cycle: Lessons from clinical trials
Philip R. Greipp, MD

Genomics and the control of cell cycle
John D. Shaughnessy Jr., PhD

Cell cycle dysregulation in myeloma: Basic science perspective
Selina Chen-Kiang, PhD

Session II: New diagnostic and prognostic methods: New dilemmas
Chair: Morton Coleman, MD

PET CT in multiple myeloma
Lale Kostakoglu, MD

Free light chain analysis in multiple myeloma
Graham Mead, MD

Cytogenetics and molecular prognostic models
Rafael Fonseca, MD

What is the latest in staging and response criteria?
S. Vincent Rajkumar, MD

Session III: Atypical plasmacytic disorders
Chair: Richard R. Furman, MD

POEMS: New advances in diagnosis and treatment
Angela Dispenzieri, MD

Session IV: Treatment I
Chair: Ruben Niesvizky, MD

IMiDs and other immunomodulator combinations
Ruben Niesvizky, MD

Proteasome inhibitors and other combinations
Donna Weber, MD

High risk myeloma: New algorithms and reduced intensity allografts
David Vesole, MD, PhD, FACP

Does transplantation have a future with the advent of novel therapies?
Bart Barlogie, MD, PhD

Session V: Treatment II
Chair: Raymond Alexanian, MD

Maximizing benefit, minimizing risk with bisphosphonate therapy
G. David Roodman, MD, PhD

Translational research: New drugs
Paul G. Richardson, MD

Session VI: Waldenstrom’s macroglobulinemia and amyloidosis
Chair: Richard R. Furman, MD

Diagnostic and response criteria in WM
Robert A. Kyle, MD

Current treatment strategies for WM
Richard R. Furman, MD

Amyloidosis: A risk based model for treatment
Raymond L. Comenzo, MD

Session VII: Chronic lymphocytic leukemia: Biology
Chair: Richard R. Furman, MD

Origin of the CLL lymphocyte: telomere length, kinetics, and markers
Nicholas Chiorazzi, MD

MicroRNAs: Their role in CLL and cancer biology
James Dahlberg, PhD

New prognostic factors in CLL
Emilio Montserrat, MD

Session VIII: Chronic lymphocytic leukemia: Therapy
Chair: Asher A. Chanan-Khan, MD

Front-line therapy: What is the current standard of care?
Neil E. Kay, MD

Second-line therapy in CLL
Asher A. Chanan-Khan, MD

Novel agents and combinations in CLL
Richard R. Furman, MD

Lymphoma Section

Session IX: Hodgkin’s disease
Chair: David J. Straus, MD

What is the best management of early stage disease
David J. Straus, MD

What is the best management of advanced disease: ABVD, Stanford V, BEACOPP or others?
Sandra J. Horning, MD

A second opinion from the German Hodgkin Study Group
Volker Diehl, MD

How best to treat lymphocytic-predominant Hodgkin’s disease
Carol S. Portlock, MD

Session X: Marginal zone and mantle cell lymphomas
Chair: Saul A. Rosenberg, MD

Optimal management of marginal zone lymphoma
Emanuele Zucca, MD

Mantle cell lymphoma biology and prognostic indicators
Randy D. Gascoyne, MD

Optimal therapy in mantle cell lymphoma
Andrew D. Zelenetz, MD

Saturday, October 20, 2007 – General Session

Session XI: Lymphoma classification
Chair: Amy Chadburn, MD

Update on lymphoma classification
Amy Chadburn, MD

Session XII: Aggressive lymphoma
Chair: Morton Coleman, MD

Targeting BCL-6 and other peptides in LCL
Ari Melnick, MD

Update in the management of LCL
Richard I. Fisher, MD

PET scanning: Changing the paradigm of therapy for LCL and Hodgkin’s?
Morton Coleman, MD

Session XIII: Follicular lymphomas
Chair: John P. Leonard, MD

Initial therapy for follicular lymphoma
John P. Leonard, MD

New strategies in the treatment of follicular lymphoma
Bruce D. Cheson, MD

Clinical benefit of vaccines in follicular lymphoma
Maurizio Bendandi, MD, PhD

Debate:
The case for maintenance anti-CD20 therapy in FL
David G. Maloney, MD, PhD

The case against maintenance anti-CD20 therapy in FL
Robert O. Dillman, MD, FACP

Workshop 1: Lymphoma & myeloma agents in early development I
Chairs: John P. Leonard, MD and Ruben Niesvizky, MD

Heat shock protein 90 inhibitors
Kenneth C. Anderson, MD, MA

HDAC inhibitors
Francine Foss, MD

New proteasome inhibitors
Kenneth C. Anderson, MD, MA

CDK4/6 inhibitors
Selena Chen-Kiang, PhD

Folate antagonists
Francine Foss, MD

Workshop 2: Lymphoma & myeloma agents in early development II
Chairs: John P. Leonard, MD and Ruben Niesvizky, MD

Monoclonal antibodies
Myron S. Czuczman, MD

mTOR inhibitors
Sonali M. Smith, MD

CD30-directed therapies
Anas Younes, MD

Bcl-2 inhibitors
Wyndham H. Wilson, MD, PhD

Metronomic therapy: Targeting angiogenesis
Jia Ruan, MD, PhD

Click here for the CME evaluation / post-test